News
Compass Pathways fell on Phase 3 data but remains on track for an FDA filing despite dilution risks and volatility. Find out ...
Seventy per cent of participant enrolment has been completed for the Phase III clinical trial of indigenous one-shot dengue ...
The global burden of influenza remains heavy, with an estimated 650,000 annual deaths worldwide and an average of 88,000 annual deaths in China, resulting in significant economic costs from healthcare ...
Q2 2025 Earnings Call Transcript August 1, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.62065 EPS, expectations were $-0.23. Operator: Greetings, and welcome to the ...
These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...
India's one-shot dengue vaccine 'DengiAll' reaches 70% enrolment in Phase III trials across 20 national sites.
Key Points GAAP revenue surpassed expectations, reaching $12.5 million in Q2 2025, Revenue reached $12.5 million, up approximately 45.3% from the prior year period. Net loss (GAAP) widened to $112.0 ...
Q2 2025 Earnings Call Transcript July 31, 2025 Operator: Good afternoon, and welcome to TransMedics Second Quarter 2025 ...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...
The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...
In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results